{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T01:15:37Z","timestamp":1724462137776},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,30]]},"DOI":"10.7759\/cureus.34384","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T14:34:20Z","timestamp":1675089260000},"source":"Crossref","is-referenced-by-count":2,"title":["A Meta-Analysis Evaluating the Effectiveness and Safety of Upadacitinib in Treating Rheumatoid Arthritis in Patients With Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs"],"prefix":"10.7759","author":[{"given":"Viraj","family":"Panchal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavya H","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barath Prashanth","family":"Sivasubramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanan","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshank","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes113","article-title":"Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis","volume":"51","author":"Choy E","year":"2012","unstructured":"Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012, 51:v3-11. 10.1093\/rheumatology\/kes113","journal-title":"Rheumatology (Oxford)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0627-z","article-title":"The role of autoantibodies in the pathophysiology of rheumatoid arthritis","volume":"39","author":"Derksen VF","year":"2017","unstructured":"Derksen VF, Huizinga TW, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 2017, 39:437-46. 10.1007\/s00281-017-0627-z","journal-title":"Semin Immunopathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis GE","year":"2019","unstructured":"Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019, 58:i43-54. 10.1093\/rheumatology\/key276","journal-title":"Rheumatology (Oxford)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz DM","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017, 16:843-62. 10.1038\/nrd.2017.201","journal-title":"Nat Rev Drug Discov"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes IB","year":"2017","unstructured":"McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017, 389:2328-37. 10.1016\/S0140-6736(17)31472-1","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen JS","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al.. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019, 393:2303-11. 10.1016\/S0140-6736(19)30419-2","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.39801","article-title":"A Phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer JM","year":"2016","unstructured":"Kremer JM, Emery P, Camp HS, et al.. A Phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol. 2016, 68:2867-77. 10.1002\/art.39801","journal-title":"Arthritis Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a Phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese MC","year":"2016","unstructured":"Genovese MC, Smolen JS, Weinblatt ME, et al.. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a Phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016, 68:2857-66. 10.1002\/art.39808","journal-title":"Arthritis Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester GR","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, et al.. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018, 391:2503-12. 10.1016\/S0140-6736(18)31115-2","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese MC","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, et al.. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018, 391:2513-24. 10.1016\/S0140-6736(18)31116-4","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a Phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann R","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, et al.. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a Phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019, 71:1788-800. 10.1002\/art.41032","journal-title":"Arthritis Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study","volume":"59","author":"Kameda H","year":"2020","unstructured":"Kameda H, Takeuchi T, Yamaoka K, et al.. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study. Rheumatology (Oxford). 2020, 59:3303-13. 10.1093\/rheumatology\/keaa084","journal-title":"Rheumatology (Oxford)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021, 134:103-12. 10.1016\/j.jclinepi.2021.02.003","journal-title":"J Clin Epidemiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson DT","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, et al.. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995, 38:727-35. 10.1002\/art.1780380602","journal-title":"Arthritis Rheum"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (select-early): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven R","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, et al.. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (select-early): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020, 72:1607-20. 10.1002\/art.41384","journal-title":"Arthritis Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.2059","article-title":"Sat0151 efficacy and safety of upadacitinib versus abatacept in patients with active rheumatoid arthritis and prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (select-choice): a double-blind, randomized controlled phase 3 trial","volume":"79","author":"Rubbert-Roth A","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan A, et al.. Sat0151 efficacy and safety of upadacitinib versus abatacept in patients with active rheumatoid arthritis and prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (select-choice): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020, 79:1015-6. 10.1136\/annrheumdis-2020-eular.2059","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-005-1355-8","article-title":"Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines","volume":"54","author":"Herman S","year":"2005","unstructured":"Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res. 2005, 54:273-80. 10.1007\/s00011-005-1355-8","journal-title":"Inflamm Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-019-0601-3","article-title":"Comparative efficacy and safety of 15 and 30\u202fmg upadacitinib administered to patients with active rheumatoid arthritis: a\u00a0Bayesian network meta-analysis of randomized controlled trials","volume":"79","author":"Song GG","year":"2020","unstructured":"Song GG, Lee YH. Comparative efficacy and safety of 15 and 30\u202fmg upadacitinib administered to patients with active rheumatoid arthritis: a\u00a0Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol. 2020, 79:103-11. 10.1007\/s00393-019-0601-3","journal-title":"Z Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1544892","article-title":"Upadacitinib for the treatment of rheumatoid arthritis","volume":"15","author":"Serhal L","year":"2019","unstructured":"Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019, 15:13-25. 10.1080\/1744666X.2019.1544892","journal-title":"Expert Rev Clin Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1671","article-title":"Exposure-response analyses of upadacitinib efficacy and safety in Phase II and III studies to support benefit-risk assessment in rheumatoid arthritis","volume":"107","author":"Nader A","year":"2020","unstructured":"Nader A, Mohamed MF, Winzenborg I, Doelger E, Noertersheuser P, Pangan AL, Othman AA. Exposure-response analyses of upadacitinib efficacy and safety in Phase II and III studies to support benefit-risk assessment in rheumatoid arthritis. Clin Pharmacol Ther. 2020, 107:994-1003. 10.1002\/cpt.1671","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/131474-a-meta-analysis-evaluating-the-effectiveness-and-safety-of-upadacitinib-in-treating-rheumatoid-arthritis-in-patients-with-inadequate-response-to-disease-modifying-anti-rheumatic-drugs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:51:25Z","timestamp":1707508285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/131474-a-meta-analysis-evaluating-the-effectiveness-and-safety-of-upadacitinib-in-treating-rheumatoid-arthritis-in-patients-with-inadequate-response-to-disease-modifying-anti-rheumatic-drugs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.34384","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,30]]}}}